NAII 10-K: Going Concern Warning, Covenant Breach Forecast, and $10.4M Impairment
NAII is trading near its 52-week low of $1.7 (0.0% above the low) on light trading volume (0.1× avg).
Summary
NAII's 10-K reveals a going concern warning, an expected debt covenant breach, a $10.4M impairment, and a strategic alternatives review including a possible sale of the company.
Updates
· GlobeNewswire — Q4 net loss was $13.5M, or $2.23 per share, on net sales of $34.5M; fiscal 2026 net loss was $20.7M, or $3.43 per share, on net sales of $142.5M. Cash was $7.5M and working capital $27.7M at June 30, 2026.
Key Events · Earnings and Guidance · NAII
-
Going Concern Warning
Substantial doubt about the company's ability to continue as a going concern has been raised by both the auditor and management, citing continued net losses, negative operating cash flows, and a forecasted covenant breach.
-
Debt Covenant Breach Forecast
The company expects to fail the fixed charge coverage ratio covenant under its Legacy credit facility as of September 30, 2026, after a largest customer materially cut its fiscal 2027 order forecast.
-
$10.4M Impairment Charge
A non-cash impairment of $10.4 million was recorded on the Carlsbad manufacturing facility, driven by declining fair value and negative cash flow projections.
-
Asset Sales and Strategic Review
The board approved the sale of the Carlsbad manufacturing facility and corporate headquarters; management initiated a strategic alternatives review including potential mergers, acquisitions, or a sale of the company.
Analysis · NAII · Life Sciences
Both the auditor and management have expressed substantial doubt about the company's ability to continue as a going concern. The company expects to breach its fixed charge coverage ratio covenant on September 30, 2026, after a major customer slashed its fiscal 2027 order forecast. A $10.4 million non-cash impairment on the Carlsbad facility wiped out a large portion of book equity. Management is selling both properties and exploring a strategic sale of the company. This is a thesis-altering disclosure for a micro-cap stock trading near its 52-week low.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAII was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $1.70 to $4.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.